Collectively, these data indicate that myeloid cell function is orchestrated by both VEGF and PD-1 pathways, highlighting the rationale for therapeutic PD-1/PD-L1 plus VEGF inhibition in cancers in which myeloid-driven immunosuppression blunts an effective anticancer immune response. Here, VEGFA is linked to cancer.